ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0790

CoLchicine for Treatment of OsteoArthritis of the Knee: Clinical Outcomes from a 90-day Double-Blind, Placebo-Controlled Study

Jonathan Samuels1, Katherine Tse2, Wei David2, maryfe Coronel2, Fernando Bomfim2, Renata La Rocca Vieira3, Nicole Leung4, Svetlana Krasnokutsky Samuels5, Michael Toprover6 and Michael Pillinger7, 1NYU Langone, Rye Brook, NY, 2NYU Langone Health, new york, NY, 3NYU., New York, NY, 4New York University Langone Medical Center, New York, NY, 5Summit Health, Rye Brook, NY, 6New York University Langone Health, New York, NY, 7New York University Grossman School of Medicine, New York,, NY

Meeting: ACR Convergence 2024

Keywords: clinical trial, Osteoarthritis, pain, Ultrasound

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 16, 2024

Title: Abstracts: Osteoarthritis – Clinical Trials

Session Type: Abstract Session

Session Time: 1:00PM-2:30PM

Background/Purpose: Knee osteoarthritis (OA) leads to progressive disability, but approved pharmacologic treatments target analgesia without affecting disease course. Colchicine is well-tolerated and inhibits inflammation thought to modulate OA, but trials to date have yielded mixed results. We tested whether daily colchicine improves pain, function and synovial effusion size in patients with knee OA.

Methods: 120 participants with painful knee OA and radiographic Kellgren-Lawrence grades 2 or 3 were enrolled, excluding individuals with inflammatory or crystal arthritis.   Participants were randomized to receive daily colchicine or placebo (1:1) for 12 weeks, while avoiding other anti-inflammatory agents.  The primary outcome was change in visual analog scale (VAS) for signal knee pain. Secondary outcomes included changes in the Knee Osteoarthritis Outcome Score (KOOS) subscales (pain, other symptoms, activities of daily living, sports and recreation, quality of life) and in the size of sonographically-identified effusions. 

Results: The colchicine and placebo groups were similar at baseline in age, race, gender, ethnicity, VAS pain, and mean levels of serum urate, with a slightly higher mean C-reactive protein (CRP) and radiographic severity in the colchicine group. From baseline to end of treatment for the colchicine vs. placebo groups, we observed no significant between-group differences in mean changes of  VAS pain ( -1.1±2.3 vs. -1.5±2.6, p=0.40, Fig. 1C), KOOS subscores (for pain: 3.4±18.7 vs. 9.8±19.9, p= 0.09, Fig. 1D with other KOOS subscores in Fig. 2A) or sonographic size of synovial effusions in millimeters (-0.35 ±3.7 vs.  -0.26 ±3.2, p= 0.93, Fig. 2B). These findings for the entire cohort remained when analyzing the per-protocol study completer subset (n=100). The subsets of patients with greater baseline inflammation (CRP or serum urate), or more severe VAS pain or radiographic KL severity, also failed to demonstrate a significant benefit from colchicine vs placebo.  Acetaminophen use was permitted as needed, but was not taken less often by patients in the colchicine group.

Conclusion: In this largest double-blind controlled study of colchicine for treatment of knee OA, colchicine failed to improve knee pain, function, or size of synovial effusions.  Whether longer treatment with colchicine, higher doses, or a larger cohort would improve pain and function or modify radiographic progression remains to be determined. Current analyses of biomarker levels from these patients’ blood and synovial fluid samples at baseline and 12 weeks will help determine if there is a biochemical effect of colchicine on OA, even if it is not manifesting clinically in a short period of time.

Supported by an Investigator Award from the Rheumatology Research Foundation (to SK-S) and by an investigator-initiated grant from Hikma Pharmaceuticals (to MHP)

Supporting image 1

Fig 1. Absolute pain scores for placebo and colchicine at baseline and after treatment, for (A) VAS score, and (B) KOOS pain, and comparison of mean change between groups for (C) VAS and (D) KOOS.

Supporting image 2

Fig 2. (A) Comparison of changes in KOOS subscores for ADL, Sports/Recreation activities, QOL and other symptoms before and after treatment with colchicine or placebo. (B) Change in effusion size before and after treatment.


Disclosures: J. Samuels: None; K. Tse: None; W. David: None; m. Coronel: None; F. Bomfim: None; R. La Rocca Vieira: None; N. Leung: None; S. Krasnokutsky Samuels: None; M. Toprover: Horizon Pharma, 1; M. Pillinger: Amgen, 2, Federation Bio, 2, Fortress Bioscience and Scilex, 2, Hikma Pharmaceuticals, 5.

To cite this abstract in AMA style:

Samuels J, Tse K, David W, Coronel m, Bomfim F, La Rocca Vieira R, Leung N, Krasnokutsky Samuels S, Toprover M, Pillinger M. CoLchicine for Treatment of OsteoArthritis of the Knee: Clinical Outcomes from a 90-day Double-Blind, Placebo-Controlled Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/colchicine-for-treatment-of-osteoarthritis-of-the-knee-clinical-outcomes-from-a-90-day-double-blind-placebo-controlled-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/colchicine-for-treatment-of-osteoarthritis-of-the-knee-clinical-outcomes-from-a-90-day-double-blind-placebo-controlled-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology